Tredje AP fonden Sells 3,705 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Tredje AP fonden reduced its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 23.3% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 12,202 shares of the biopharmaceutical company’s stock after selling 3,705 shares during the quarter. Tredje AP fonden’s holdings in Alnylam Pharmaceuticals were worth $3,979,000 at the end of the most recent reporting period.

Several other institutional investors have also made changes to their positions in the stock. Bayforest Capital Ltd lifted its position in shares of Alnylam Pharmaceuticals by 14.6% during the 1st quarter. Bayforest Capital Ltd now owns 306 shares of the biopharmaceutical company’s stock valued at $83,000 after acquiring an additional 39 shares during the period. Fulton Bank N.A. lifted its position in Alnylam Pharmaceuticals by 3.3% during the second quarter. Fulton Bank N.A. now owns 1,421 shares of the biopharmaceutical company’s stock worth $463,000 after purchasing an additional 46 shares during the period. Northwestern Mutual Wealth Management Co. lifted its position in Alnylam Pharmaceuticals by 10.3% during the first quarter. Northwestern Mutual Wealth Management Co. now owns 525 shares of the biopharmaceutical company’s stock worth $142,000 after purchasing an additional 49 shares during the period. Edmond DE Rothschild Holding S.A. lifted its position in Alnylam Pharmaceuticals by 18.2% during the first quarter. Edmond DE Rothschild Holding S.A. now owns 318 shares of the biopharmaceutical company’s stock worth $86,000 after purchasing an additional 49 shares during the period. Finally, Lindbrook Capital LLC lifted its position in Alnylam Pharmaceuticals by 9.2% during the first quarter. Lindbrook Capital LLC now owns 596 shares of the biopharmaceutical company’s stock worth $161,000 after purchasing an additional 50 shares during the period. 92.97% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. HC Wainwright reaffirmed a “buy” rating and set a $570.00 price target on shares of Alnylam Pharmaceuticals in a report on Friday, October 10th. Jefferies Financial Group cut their target price on Alnylam Pharmaceuticals from $550.00 to $549.00 and set a “buy” rating for the company in a research note on Thursday. Wall Street Zen cut Alnylam Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research note on Sunday. The Goldman Sachs Group upped their target price on Alnylam Pharmaceuticals from $504.00 to $566.00 and gave the stock a “buy” rating in a research note on Tuesday, September 16th. Finally, Scotiabank upped their price objective on Alnylam Pharmaceuticals from $342.00 to $450.00 and gave the stock a “sector outperform” rating in a research report on Friday, August 1st. Twenty-three equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $478.67.

Insider Transactions at Alnylam Pharmaceuticals

In related news, Director Dennis A. Ausiello sold 31,448 shares of the firm’s stock in a transaction that occurred on Thursday, August 14th. The shares were sold at an average price of $436.58, for a total value of $13,729,567.84. Following the completion of the transaction, the director owned 911 shares in the company, valued at $397,724.38. This trade represents a 97.18% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Colleen F. Reitan sold 18,000 shares of the firm’s stock in a transaction on Tuesday, September 9th. The shares were sold at an average price of $467.60, for a total transaction of $8,416,800.00. Following the transaction, the director directly owned 775 shares of the company’s stock, valued at $362,390. The trade was a 95.87% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders sold 98,144 shares of company stock valued at $44,160,261. 1.50% of the stock is currently owned by corporate insiders.

Alnylam Pharmaceuticals Stock Up 1.4%

Shares of ALNY opened at $456.04 on Monday. Alnylam Pharmaceuticals, Inc. has a 52 week low of $205.87 and a 52 week high of $495.55. The stock has a market capitalization of $59.78 billion, a price-to-earnings ratio of -184.63 and a beta of 0.36. The company has a debt-to-equity ratio of 4.10, a quick ratio of 2.75 and a current ratio of 2.80. The stock has a fifty day moving average of $460.19 and a 200-day moving average of $370.92.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last announced its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported $2.90 EPS for the quarter, beating analysts’ consensus estimates of $1.39 by $1.51. The company had revenue of $1.25 billion during the quarter, compared to analysts’ expectations of $943.37 million. Alnylam Pharmaceuticals had a negative return on equity of 273.52% and a negative net margin of 12.96%.Alnylam Pharmaceuticals’s revenue was up 149.3% compared to the same quarter last year. During the same period in the prior year, the company earned ($0.50) EPS. Alnylam Pharmaceuticals has set its FY 2025 guidance at EPS. As a group, sell-side analysts anticipate that Alnylam Pharmaceuticals, Inc. will post -1.7 earnings per share for the current fiscal year.

Alnylam Pharmaceuticals Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.